Skip to main content
SpringerLink
Log in

Hypertension and hepatic steatosis

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Hepatic steatosis (fatty liver) is increasingly recognized as a major component of the metabolic (insulin resistance) syndrome. It can progress to cirrhosis and hepatocellular carcinoma, leading to liver-related mortality. Increasing evidence shows a significant association between hepatic steatosis and hypertension; both are linked to the metabolic syndrome. This review discusses the evidence to support this association, and reviews the diagnosis and management of hepatic steatosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Brookes MJ, Cooper BT: Hypertension and fatty liver: guilty by association? J Hum Hypertens 2007, 21:264–270.

    PubMed  CAS  Google Scholar 

  2. Harrison SA, Day CP: Benefits of lifestyle modification in NAFLD. Gut 2007, 56:1760–1769.

    Article  PubMed  CAS  Google Scholar 

  3. Machado M, Marques-Vidal P, Cortez-Pinto H: Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006, 45:600–606.

    Article  PubMed  Google Scholar 

  4. Duvnjak M, Lerotic I, Barsic N, et al.: Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007, 13:4539–4550.

    PubMed  CAS  Google Scholar 

  5. Lee DH, Ha MH, Kim KY, et al.: Gamma-glutamyltransferase: an effect modifier in the association between age and hypertension in a 4-year follow-up study. J Hum Hypertens 2004, 18:803–807.

    Article  PubMed  CAS  Google Scholar 

  6. Stranges S, Trevisan M, Dorn JM, et al.: Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study. Hypertension 2005, 46:1186–1193.

    Article  PubMed  CAS  Google Scholar 

  7. Donati G, Stagni B, Piscaglia F, et al.: Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004, 53:1020–1023.

    Article  PubMed  CAS  Google Scholar 

  8. Dam-Larsen S, Franzmann M, Andersen IB, et al.: Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004, 53:750–755.

    Article  PubMed  CAS  Google Scholar 

  9. McCullough AJ: The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004, 8:521–533, viii.

    Article  PubMed  Google Scholar 

  10. Liou I, Kowdley KV: Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006, 40(3 suppl 1):S11–S16.

    PubMed  Google Scholar 

  11. Donnelly KL, Smith CI, Schwarzenberg SJ, et al.: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343–1351.

    PubMed  CAS  Google Scholar 

  12. Cai DS, Yuan MS, Frantz DF, et al.: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med 2005, 11:183–190.

    Article  PubMed  CAS  Google Scholar 

  13. Samuel VT, Liu ZX, Qu XQ, et al.: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004, 279:32345–32353.

    Article  PubMed  CAS  Google Scholar 

  14. Albano E, Mottaran E, Occhino G, et al.: Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 2005, 22:71–73.

    Article  PubMed  Google Scholar 

  15. Albano E, Mottaran E, Vidali M, et al.: Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005, 54:987–993.

    Article  PubMed  CAS  Google Scholar 

  16. Zamara E, Novo E, Marra F, et al.: 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 2004, 40:60–68.

    Article  PubMed  CAS  Google Scholar 

  17. Cortez-Pinto H, de Moura MC, Day CP: Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006, 44:197–208.

    Article  PubMed  CAS  Google Scholar 

  18. Ribeiro PS, Cortez-Pinto H, Sola S, et al.: Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappa B in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004, 99:1708–1717.

    Article  PubMed  CAS  Google Scholar 

  19. Arkan MC, Hevener AL, Greten FR, et al.: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11:191–198.

    Article  PubMed  CAS  Google Scholar 

  20. Feldstein AE, Werneburg NW, Canbay A, et al.: Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40:185–194.

    Article  PubMed  CAS  Google Scholar 

  21. Angulo P, Alba LM, Petrovic LM, et al.: Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004, 41:943–949.

    Article  PubMed  CAS  Google Scholar 

  22. Yokohama S, Tokusashi Y, Nakamura K, et al.: Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006, 12:322–326.

    PubMed  CAS  Google Scholar 

  23. Targher G, Bertolini L, Rodella S, et al.: Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006, 64:337–341.

    Article  CAS  Google Scholar 

  24. Ataseven H, Yildirim MH, Yalniz M, et al.: The value of ultrasonography and computerized tomography in estimating the histopathological severity of nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2005, 68:221–225.

    PubMed  CAS  Google Scholar 

  25. Szczepaniak LS, Nurenberg P, Leonard D, et al.: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005, 288:E462–E468.

    Article  PubMed  CAS  Google Scholar 

  26. Yeh MM, Brunt EM: Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007, 128:837–847.

    Article  PubMed  Google Scholar 

  27. O’Leary VB, Marchetti CM, Krishnan RK, et al.: Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat. J Appl Physiol 2006, 100:1584–1589.

    Article  PubMed  CAS  Google Scholar 

  28. Tiikkainen M, Bergholm R, Rissanen A, et al.: Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr 2004, 79:22–30.

    PubMed  CAS  Google Scholar 

  29. Zelber-Sagi S, Kessler A, Brazowsky E, et al.: A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4:639–644.

    Article  PubMed  CAS  Google Scholar 

  30. Stratopoulos C, Papakonstantinou A, Terzis I, et al.: Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005, 15:1154–1160.

    Article  PubMed  Google Scholar 

  31. Jaskiewicz K, Raczynska S, Rzepko R, et al.: Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci 2006, 51:21–26.

    Article  PubMed  CAS  Google Scholar 

  32. Shaffer EA: Bariatric surgery: a promising solution for nonalcoholic steatohepatitis in the very obese. J Clin Gastroenterol 2006, 40:S44–S50.

    Article  PubMed  Google Scholar 

  33. Barker KB, Palekar NA, Bowers SP, et al.: Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006, 101:368–373.

    Article  PubMed  Google Scholar 

  34. Uygun A, Kadayifci A, Isik AT, et al.: Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004, 19:537–544.

    Article  PubMed  CAS  Google Scholar 

  35. Bugianesi E, Gentilcore E, Manini R, et al.: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082–1090.

    Article  PubMed  CAS  Google Scholar 

  36. Duseja A, Das A, Dhiman RK, et al.: Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007, 6:222–226.

    PubMed  CAS  Google Scholar 

  37. Kawaguchi K, Sakaida I, Tsuchiya M, et al.: Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2004, 315:187–195.

    Article  PubMed  CAS  Google Scholar 

  38. Promrat K, Lutchman G, Uwaifo GI, et al.: A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188–196.

    Article  PubMed  CAS  Google Scholar 

  39. Sanyal AJ, Mofrad PS, Contos MJ, et al.: A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004, 2:1107–1115.

    Article  PubMed  CAS  Google Scholar 

  40. Lutchman G, Promrat K, Kleiner DE, et al.: Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006, 4:1048–1052.

    Article  PubMed  CAS  Google Scholar 

  41. Ono M, Ikegami H, Fujisawa T, et al.: Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones. Metabolism 2005, 54:529–532.

    Article  PubMed  CAS  Google Scholar 

  42. Wang CH, Leung CH, Liu SC, et al.: Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic fatty liver disease. J Formos Med Assoc 2006, 105:743–752.

    Article  PubMed  CAS  Google Scholar 

  43. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.

    Article  PubMed  CAS  Google Scholar 

  44. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, et al.: A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643–1647.

    Article  PubMed  CAS  Google Scholar 

  45. Hatzitolios A, Savopoulos C, Lazaraki G, et al.: Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004, 23:131–134.

    PubMed  Google Scholar 

  46. Lindor KD, Kowdley KV, Heathcote EJ, et al.: Ursodeoxycholic acid for treatment of nonalcoholics steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770–778.

    Article  PubMed  CAS  Google Scholar 

  47. Dufour JF, Oneta CM, Gonvers JJ, et al.: Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006, 4:1537–1543.

    Article  PubMed  CAS  Google Scholar 

  48. Kanno K, Tazuma S, Nishioka T, et al.: Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Dig Dis Sci 2005, 50:942–948.

    Article  PubMed  CAS  Google Scholar 

  49. Yokohama S, Yoneda M, Haneda M, et al.: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222–1225.

    Article  PubMed  CAS  Google Scholar 

  50. Satapathy SK, Sakhuja P, Malhotra V, et al.: Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22:634–638.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Unit, City Hospital, Dudley Road, Birmingham, B18 7QH, UK

    Brian T. Cooper

Authors
  1. Matthew J. Brookes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tariq H. Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brian T. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian T. Cooper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brookes, M.J., Iqbal, T.H. & Cooper, B.T. Hypertension and hepatic steatosis. Current Science Inc 10, 182–187 (2008). https://doi.org/10.1007/s11906-008-0035-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-008-0035-9

Keywords

Search

Navigation